Uriviga M 25 Tablet contains Tamsulosin 0.4mg + Mirabegron 25mg, a dual-action therapy for urinary tract management, including bladder outlet obstruction and overactive bladder. Tamsulosin relaxes smooth muscles of the urinary tract to improve urine flow, while Mirabegron reduces bladder overactivity, ensuring comprehensive symptom control and improved patient comfort.
The combination is well-regarded by prescribers due to its efficacy, tolerability, and patient-friendly dosing, generating consistent demand. Patients benefit from enhanced urinary function, reduced urgency and frequency, and better adherence to treatment.
For franchise partners, Uriviga M 25 Tablet is a high-demand urology product with strong market potential. Its proven clinical performance and prescriber confidence make it a profitable addition to urology portfolios, supporting business growth and long-term customer retention.
With its dual benefit of urinary relief and bladder health support, Uriviga M 25 Tablet offers sustainable sales opportunities, making it an excellent choice for partners serving the urology and urinary care segment.